FCCC LOGO Faculty Publications
Stevenson JP , Scher RM , Kosierowski R , Fox SC , Simmonds M , Yao KS , Green F , Broom C , Fields SZ , Krebs JB , O'Dwyer PJ
Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas
European Journal of Cancer. 1998 Aug;34(9) :1358-1362
PMID: ISI:000075290600012   
Back to previous list
Abstract
The aim of this study was to determine the efficacy and toxicity of topotecan administered as a 21-day continuous intravenous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. 26 previously untreated patients with advanced or metastatic pancreatic adenocarcinoma received topotecan at a dose of 0.5 mg/m(2)/day or 0.6 mg/m(2)/day as a continuous intravenous infusion for 21 days. Courses were repeated every 28 days. 26 patients were assessable for response and toxicity on an intent-to-treat basis. The initial 8 patients at a starting dose of 0.6 mg/m(2)/day experienced unacceptable myelosuppression and dose delays. The subsequent 18 patients, therefore began therapy at a dose of 0.5 mg/m(2)/day. The major toxicity of topotecan at this dose and schedule was myelosuppression, which was reversible and non-cumulative. There were no complete responses and two partial responses for a total response rate of 8% (95% confidence interval, 1-25%). Response durations were 17 and 45 weeks. Stable disease was seen in 3 patients. The median time to progression for all patients was 8 weeks and the median survival was 20 weeks. Topotecan given as a 21-day continuous intravenous infusion has a similar response rate and median survival to our previously reported study of the 5-day short infusion regimen in pancreatic carcinoma. (C) 1998 Elsevier Science Ltd. All rights reserved.
Notes
Times Cited: 10 English Article 108XG EUR J CANCER